Article thumbnail

Recent results of cetuximab use in the treatment of squamous cell carcinoma of the head and neck

By Francesco Perri, Francesco Longo, Franco Ionna and Francesco Caponigro

Abstract

Cetuximab is a chimeric monoclonal antibody that targets the epidermal growth factor receptor. The role of cetuximab is paramount in several subsets of head and neck cancer. In particular, the EXTREME study has indicated cetuximab as the only drug to improve survival when associated with cisplatin and 5-fluorouracil in patients with recurrent/metastatic disease. Furthermore, cetuximab, both alone and in combination with cisplatin, is active in patients with recurrent/metastatic disease who have failed prior platinum-based chemotherapy. Cetuximab, given in association with radiation therapy, is a treatment of choice in first-line therapy of patients with locally advanced inoperable disease. In the same setting, the role of induction chemotherapy has gained considerable interest over the last few years and a number of efforts are being pursued to optimally integrate induction chemotherapy with radiation therapy plus cetuximab. The combination of cetuximab and other targeted therapies is among the most promising new perspectives for patients with head and neck cancer

Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:2886337
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data.
  2. (2007). Epidermal growth factor receptor (EGFR) polymorphisms and survival in head and neck cancer patients. Oral Oncol.
  3. Epidermal growth factor receptor biology in head and neck cancer.
  4. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cell cancer.
  5. (2001). Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res.
  6. Experience with cetuximab plus paclitaxel/carboplatinum in primary platinum-resistant recurrent head and neck cancer.
  7. Forastiere AA; Eastern Cooperative Oncology Group. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/ recurrent head and neck cancer: an eastern cooperative oncology group study.
  8. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinoma.
  9. (1998). Levels of TGF-a and EGFR protein in head and neck squamous cell carcinoma and patient survival.
  10. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.
  11. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
  12. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.
  13. Phase II trial to evaluate efficacy and toxicity of cetuximab plus docetaxel in platinum pretreated patients with recurrent and/or metastatic head and neck cancer [abstract].
  14. Platinum-based chemotherapy plus cetuximab in head and neck cancer.
  15. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.
  16. (2009). Practice Guidelines in Oncology. Latest update date and version number 2007–2008.
  17. Targeting the epidermal growth factor receptor.
  18. (1988). The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol.
  19. uncontrolled, multicenter, phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.